Read, Watch or Listen

Twenty-seven states and the District of Columbia filed a lawsuit to prevent 23andMe from selling its customers' genetic data without consent during its bankruptcy proceedings. The lawsuit argues that this sensitive information requires explicit consent before sale. Biotechnology company Regeneron, planning to acquire 23andMe for $256 million, claims it will adhere to privacy policies and laws. A court-appointed ombudsman is reviewing the sale's impact on consumer privacy.

Prepared by Olivia Bennett and reviewed by editorial team.